Background: Familial eosinophilia (FE) is a rare autosomal dominant inherited disor-
eosinophilia in affected family members, clinical manifestations related to the eosinophilia are uncommon. 2, 3 This "benign" phenotype is likely related to a relative lack of eosinophil activation as evidenced by cellular morphology, surface activation markers, and release of eosinophil granule proteins. 3 Although the gene responsible for FE has been mapped by genomewide linkage analysis in one large kindred to a region on chromosome 5q containing the cytokine gene cluster (multipoint logarithm of odds score of 6.49), targeted sequencing of candidate genes, including IL-5, IL-3, and GMCSF, and their promoters has failed to identify the causative mutation. 4 Attempts to identify the causative mutation by whole-genome sequencing are ongoing, but have been unsuccessful to date.
The increased levels of morphologically normal peripheral blood eosinophils observed in subjects with FE could be due to a primary abnormality in the eosinophil lineage or to mediators produced by cell types other than the eosinophil. Prior studies, including morphologic examination, ex vivo differentiation of eosinophils from CD34+ cells, and eosinophil survival assays, have provided little evidence for a primary eosinophil defect. 3 Although serum cytokine levels measured previously were similar between affected and unaffected family members, the assay used to measure IL-5 was relatively insensitive, detecting IL-5 in sera from only three of 14 affected and three of 22 unaffected family members. 1 The aim of this study was to identify the cell population(s) responsible for driving the eosinophilia in FE.
| PATIENT POPULATION AND METHODS

| Study subjects
Affected and unaffected family members from two kindreds with autosomal dominant hypereosinophilia (HE; absolute eosinophil count >1500/lL) documented over at least three generations were evaluated on institutional review board-approved clinical protocols to study FE (NCT00091871 and a prior protocol that preceded clinicaltrials.gov) (see pedigrees in Fig. S1 ). Healthy controls (HC) without eosinophilia were recruited on a separate institutional review board-approved clinical protocol to obtain normal blood samples for in vitro research (NCT00001846). All participants gave written informed consent. As described previously, 3 Scanner 3000. Array images were analyzed using Affymetrix Gene
Chip Operating System (GCOS) software using the MAS5 algorithm. levels were quantified in serum using an in-house chemiluminescence capture ELISA as previously described. 8 
| Statistical analysis
Geometric means (GM) were used for measurements of central tendency. Group means were compared using the Mann-Whitney test, and paired samples were analyzed using the Wilcoxon signed rank test. A P-value of <.05 was considered statistically significant for all tests. For the microarray data, the table of gene probe set expression estimates (using the MAS5 algorithm) for 17 arrays (nine affected subjects, eight unaffected) was transformed by quantile normalization before calculating expression differences between the two groups using the SAS mixed-effects ANOVA procedure in JMP/Genomics version 8.0 (SAS Institute, Cary, NC, USA). P-values were adjusted for multiple testing using the False Discovery Rate method. . Serum levels of sIL-5Ra, a surrogate marker of cytokine-driven eosinophilia, 8 were also significantly increased in affected family members (GM 450.9 vs 174.9 ng/mL in unaffected family members; P<.01). Serum levels of GM-CSF, another cytokine that plays a role in the induction of eosinophilia and has been shown to increase serum levels of sIL-5Ra, was significantly decreased in affected family members (GM 0.37 vs 1.33 pg/mL in unaffected family members; P=.02). Surprisingly, serum levels of the eosinophilattracting chemokine, eotaxin1/CCL11, were also decreased in affected family members (GM 128.6 vs 241.2 pg/mL in unaffected family members, P=.02).
To explore whether the increased IL-5 was part of a more generalized type 2 response, serum levels of the type 2 cytokine, IL-13 (Fig. S4) . IL-4 and IL-13. Consequently, it is not difficult to imagine a scenario in which specific regulatory elements might lead to isolated expression of IL-5. 24 In fact, isolated upregulated IL-5 transcription has been shown to occur in response to mIR-1248. 6 In the present study, the lack of concomitant upregulation of RAD50 is consistent with the hypothesis that IL-5 is not being expressed under control of the previously described LCR and suggests a novel regulatory mechanism for IL-5 mRNA expression. The fact that all cell types examined expressed increased levels of IL-5 mRNA implies that this dysregulation of expression is lineage independent.
In summary, FE is a rare genetic disorder of unknown etiology characterized by persistent eosinophilia and increased IL-5 production by PBMCs. The central role of IL-5 in the production, activation, and survival of eosinophils has made it a prime target for therapeutic intervention in asthma and other eosinophilic disorders. Familial eosinophilia provides a unique opportunity to explore a novel mechanism of IL-5 regulation in humans. Ultimately, this could lead to the development of new therapeutic strategies for the treatment of eosinophilic disorders.
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